Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort.
Makito MiyakeNobutaka NishimuraYuki OdaTatsuki MiyamotoKota IidaKuniaki InoueAkira TachibanaTakanosuke YoshikawaKeichi SakamotoMikiko OhnishiFumisato MaesakaNorimi TakamatsuKosuke MiedaChihiro OhmoriToshihiko MatsubaraMitsuru TomizawaTakuto ShimizuKenta OhnishiShunta HoriYosuke MorizawaDaisuke GotohYasushi NakaiKazumasa TorimotoNobumichi TanakaKiyohide Fujimotonull nullPublished in: International journal of clinical oncology (2024)
Our study provides real-world evidence regarding difference of oncological efficacy between maintenance avelumab and subsequent pembrolizumab in patients with mUC who achieved partial response or SD on 1L-CT.
Keyphrases
- locally advanced
- rectal cancer
- radical prostatectomy
- squamous cell carcinoma
- small cell lung cancer
- computed tomography
- robot assisted
- prostate cancer
- image quality
- magnetic resonance imaging
- cross sectional
- advanced non small cell lung cancer
- contrast enhanced
- clinical trial
- radiation therapy
- liver metastases
- epidermal growth factor receptor
- chemotherapy induced